Last reviewed · How we verify
NCT05131243
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
NA trial testing Chemotherapy time in Colorectal Cancer Stage II in 100 participants. Status unknown.
1 May 2023
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 100 |
| Start date | 1 December 2021 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 May 2023 |
Drugs / interventions tested
- Chemotherapy time
- Chemotherapy time
Conditions studied
- Colorectal Cancer Stage II — all drugs for Colorectal Cancer Stage II →
- Colorectal Cancer Stage III — all drugs for Colorectal Cancer Stage III →
Sponsor
Fujian Cancer Hospital
Who can join
18 and older, any sex, with Colorectal Cancer Stage II or Colorectal Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to observe the relationship between ctDNA as a molecular marker of colorectal cancer and the risk of postoperative recurrence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05131243
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer Stage II
Currently open trials in the same condition.
- NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting
- NCT06958926 — A Translational Study for Locoregional Recurrence of T4 Colon Cancer · recruiting
- NCT07226115 — Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer · recruiting
- NCT06076811 — DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies · recruiting
- NCT05898789 — Virtual Rehabilitation for Cancer Survivors · NA · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05131243 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: 23 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05131243.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing